Ribavirin: profile and news

MIGENIX Receives Approval for MX-3253 Phase II Combination Viral ...  16 May 2006
...designed to demonstrate improved antiviral activity when celgosivir is used in combination with peginterferon alfa-2b, with or without ribavirin, as compared ... - Yahoo! News (press release)

Depressive Symptoms and Physical/Mental Functioning With ...  May 9, 2006
...e-mail: james.bourgeois{at}ucdmc.ucdavis.edu. Psychiatric comorbidity is a common problem in both hepatitis C and its treatment with interferon/ribavirin. ... - Psychosomatics (subscription)

- Interim results to date demonstrate Albuferon is safe, well ...  May 1, 2006
2 clinical trial to evaluate the safety, tolerability and efficacy of Albuferon(TM) (albumin-interferon alpha 2b) in combination with ribavirin in patients ... - Yahoo! News (press release)

Transition Therapeutics Announces Third Quarter Fiscal 2006 ...  May 15, 2006
...who have failed to respond to previous treatment with the current "gold standard" hepatitis C therapies consisting of pegylated interferon and ribavirin. ... - Canada NewsWire (press release),

Coley Pharmaceutical Group Announces Data from Clinical Study of ...  May 1, 2006
ACTILON, in Combination with Pegylated Interferon and Ribavirin, Improves Patient Response Rates Relative to Pegylated Interferon and Ribavirin Alone WELLESLEY ... - PR Newswire (press release),

Coley Pharmaceutical Group Reports First Quarter Financial Results  May 11, 2006
...to evaluate ACTILON (CPG 10101) among treatment-refractory patients infected with HCV who were previously unresponsive to pegylated interferon plus ribavirin. ... - PR Newswire (press release),

Human Genome Sciences Presents Interim Results of Phase 2b Trial ...  May 1, 2006
...from a Phase 2b clinical trial to evaluate the efficacy and safety of Albuferon(TM) (albumin- interferon alpha 2b) in combination with ribavirin in patients ... - PR Newswire (press release),

Rabies Kills Texas Boy, 16  May 15, 2006
...ketamine and Versed (midolazam). Antiviral therapy was undertaken with ribavirin and Symmetrel (amantadine). A lumbar puncture after ... - MedPage Today,

Researchers from the People's Republic of China, Australia and ...  May 15, 2006
...this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the ... - Therapeutics Daily (subscription) (press release),

Coley Pharmaceutical Group Presents Data from Clinical Study of ...  Apr 29, 2006
...the company's five-arm Phase Ib clinical study of ACTILON(TM) (CPG 10101) alone and in combinations with pegylated interferon and/or ribavirin, among treatment ... - Boursorama,

Reports from France and the United States advance knowledge in ...  May 15, 2006
C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus (HIV) and HCV and treated with interferon plus ribavirin. ... - Therapeutics Daily (subscription) (press release),

Treatment that saved a life to be tried again  May 10, 2006
England Journal of Medicine, Willoughby and his colleagues described how they treated Giese with sedating and antiviral drugs, such as ribavirin and amantadine ... - Houston Chronicle,

Coley Pharma Study Data Reveal ACTILON With Pegylated Interferon ...  May 1, 2006
...data from its treatment Phase Ib clinical study of ACTILON, alone as well as in combination with pegylated interferon and/or ribavirin, among chronically ... - Trading Markets,

Coley Pharma Reveals Positive Results From Phase Ib Clinical Study ...  Apr 29, 2006
...that the data from the four-and twelve-week clinical study of Actilon, alone and in combination with pegylated interferon and/or ribavirin indicated greater ... - Trading Markets,

PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is ...  Apr 29, 2006
Roche announced today that results from a new trial have shown that 24 weeks of therapy with PEGASYS(R) (peginterferon alfa-2a) combined with ribavirin is more ... - PR Newswire (press release),

Combination of VX-950 and Pegylated Interferon Shows Benefits in ...  May 2, 2006
April 29 th . The current treatment standard involves a combination of weekly peg-IFN and twice daily oral ribavirin. Dr. Reesink ... - DG News

Human Genome Sciences Reveals Positive Interim Results Of Phase 2b ...  May 1, 2006
The company said the study was conducted to evaluate the safety, tolerability and efficacy of Albuferon in combination with ribavirin in patients with chronic ... - Trading Markets,

New Oral Polymerase Inhibitor Shows Promising Results in Chronic ...  Apr 29, 2006
Further trials are planned to study how well R1626 works in combination with PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin). ... Use with Ribavirin. ... - Yahoo! News (press release)

Human Genome updates Albuferon data  May 1, 2006
The company followed 71 patients and found that 22 patients, or 31 percent, given Albuferon along with ribavirin had undetectable levels of the virus after 48 ... - BusinessWeek

Roche study shows hepatitis C patients need six months of ...  May 3, 2006
Roche has posted results from a new trial showing that 24 weeks of therapy with Pegasys combined with ribavirin is more effective than 16 weeks for patients ... - Pharmaceutical Business Review

MIGENIX to Present at Several Upcoming Investor and Scientific ...  May 2, 2006
...the treatment of chronic hepatitis C virus (HCV) infections currently enrolling patients in combination with peginterferon alfa-2b; with and without ribavirin. ... - Yahoo! News (press release)

Hepatitis C Patients Benefit From Combination Of VX-950 And ...  May 2, 2006
...standard dose of peg-IFN alone. Patients had not undergone prior treatment with interferon and/or ribavirin. In a 14-day study reported ... - Medical News Today (press release),

New PEGASYS(R) Trial Shows Six Months of Treatment is Optimal for ...  May 1, 2006
A major new trial has shown that 24 weeks of the hepatitis C therapy called pegylated interferon combined with ribavirin is better than 16 weeks for patients ... - PR Newswire UK (press release),

Studies from the United States and Japan describe new findings in ...  May 4, 2006
Study 1: According to research from the United States, interferon and ribavirin are promising for recurrent hepatitis C virus (HCV) infection after liver ... - Therapeutics Daily (subscription) (press release),

EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ...  Apr 26, 2006
...that sustained loss of serum HCV RNA six months following the completion of treatment with nonpegylated interferon alfa-2b (with or without ribavirin) is a ... - DG News

AVI BioPharma Presents Initial Results on Hepatitis C Virus ...  May 10, 2006
The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients ... - Genetic Engineering News,

Stealth virus  May 9, 2006
Her assessment was far more hopeful. She started Bier on an intensive combination drug regimen of pegylated interferon and ribavirin. ... - Asbury Park Press,

Gen ID to develop new bird flu drugs  May 9, 2006
Current treatment of H5N1 avian influenza infection includes the use of antiviral therapy such as ribavirin and amantadine and neuraminidase inhibitors such as ... - Pharmaceutical Business Review

Positive Interim Data for Human Genome Sciences' Hepatitis ...  May 5, 2006
...interim results from a phase IIb clinical trial to evaluate the efficacy and safety of its drug candidate Albuferon in combination with ribavirin in patients ... - International News Service,

WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and ...  Apr 28, 2006
HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-Intron(R) (peginterferon alfa-2b) in combination with Rebetol(R) (ribavirin, USP) was as ... - DG News

Hoping again for a miracle  May 11, 2006
...against rabies in rats. They gave Giese a cocktail of drugs including ketamine, midazolam, ribavirin and amantadine. Six days after ... - Milwaukee Journal Sentinel (subscription),

Human Genome Sciences Announces Results for First Quarter of 2006  May 10, 2006
..."In April 2006, HGS presented the positive interim results of two clinical trials of Albuferon(TM) in combination with ribavirin. ... - Yahoo! News (press release)

Coley Pharmaceutical Group Reports First Quarter Financial Results  May 11, 2006
...to evaluate ACTILON (CPG 10101) among treatment-refractory patients infected with HCV who were previously unresponsive to pegylated interferon plus ribavirin. - PharmaLive.com (press release),

WIN-R Study Demonstrates Efficacy of Shorter PEG-INTRON and ...  Apr 28, 2006
...virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-INTRON® (peginterferon alfa-2b) in combination with REBETOL® (ribavirin, USP) was ... - Yahoo! News (press release)

Researchers Report Initial Results for 14-day Phase Ib Study of VX ...  Apr 29, 2006
...of detection (10 IU/mL, Roche TaqMan(R)). All patients enrolled in the 14-day study subsequently received follow-on treatment with peg-IFN and ribavirin (RBV). ... - Boursorama,

Only 24 weeks of treatment may be needed for easier-to-treat HCV ...  Apr 23, 2006
Europe. Standard treatment for hepatitis C virus coinfection in HIV-positive individuals is pegylated interferon with ribavirin. ... - Aidsmap,

Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by ...  Apr 24, 2006
Phase 1b trial will evaluate NOV-205 as monotherapy for chronic hepatitis C genotype 1 patients who have failed pegylated interferon plus ribavirin therapy. ... - Genetic Engineering News,

Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH ...  Apr 19, 2006
...the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1 who were nonresponders to peginterferon and ribavirin combination therapy ... - Yahoo! News (press release)

Researchers Report Initial Results for 14-day Phase Ib Study of VX ...  Apr 29, 2006
TaqMan®). All patients enrolled in the 14-day study subsequently received follow-on treatment with peg-IFN and ribavirin (RBV). ... - Yahoo! News (press release)

Vertex Pharmaceuticals Reports First Quarter 2006 Financial ...  Apr 25, 2006
In February, Vertex announced preliminary results from a 12-patient, 28-day Phase II study of VX-950 in combination with pegylated interferon and ribavirin. ... - PR Newswire (press release),

The ticking time bomb of liver disease  May 2, 2006
...announced in Vienna is that research has shown that the long-term treatment of genotype 2 and 3 with Pegasys (peginterferon alfa- 2a) and Ribavirin will now ... - Times Online,

(PRN) - Wisconsin Energy Corporation Posts Higher Results from ...  May 1, 2006
...[+]. (PRN) - Human Genome Sciences Presents Interim Results of Phase 2b Trial of Albuferon(TM) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis ... - Bolsamania.com,

(PRN) - ClickSoftware Reports Financial Results for the First ...  May 1, 2006
...(PRN) - Human Genome Sciences Presents Interim Results of Phase 2 Trial of Albuferon(TM) with Ribavirin in Patients with Chronic Hepatitis C Who Failed to ... - Bolsamania.com,

Schering-Plough Completes Patient Enrollment In First Part Of ...  Apr 19, 2006
...for the treatment of patients chronically infected with hepatitis C virus genotype 1 who were nonresponders to peginterferon and ribavirin combination therapy. ... - Trading Markets,

Roche Oral Drug Shows Promise in Hepatitis C  May 5, 2006
Further trials are planned to study how well R1626 works in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). ... - International News Service,

AP/San Jose Mercury News Examines Implications of Schering ...  May 2, 2006
According to the company, the new treatment is for patients who are nonresponders to traditional combination therapy of interferon and ribavirin. ... - Kaiser network.org,

AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial ...  Apr 20, 2006
...composed of patients who have not received previous treatment and the other composed of patients who have failed conventional interferon and ribavirin treatment ... - Genetic Engineering News,

Valeant Pharma's 10% Growth In Revenues Cuts Q1 Loss - Update  May 4, 2006
Product sales increased 12% to $180.8 million from $161.8 million, while, Ribavirin royalties decreased 6% to $18.1 million from $19.3 million in the year ago ... - Trading Markets,

Valeant Pharmaceuticals Reports 2006 First Quarter Results ...  May 4, 2006
...compared to $161.8 million. -- Ribavirin royalties decreased 6 percent to $18.1 million compared to $19.3 million. -- Net loss was ... - Genetic Engineering News,